H. Collard (San Francisco, United States of America), C. Vancheri (Catania, Italy)
Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF)
A. Azuma, Y. Taguchi, T. Ogura, M. Ebina, H. Taniguchi, Y. Kondoh, M. Suga, H. Takahashi, K. Nakata, A. Sato, S. Kudoh, T. Nukiwa, Pirfenidone Clinical Study Group in Japan (Tokyo, Tenri City, Yokohama, Sendai, Aichi, Kumamoto, Japan)
|    |
Pirfenidone dose-response in patients with idiopathic pulmonary fibrosis (IPF): A comprehensive analysis of outcomes in CAPACITY 2
U. Costabel, C. Albera, W. Bradford, T. King, P. Noble, S. Sahn, J. Szwarcberg, D. Valeyre, R. du Bois (Essen, Germany; , Italy; Brisbane, San Francisco, Durham, Charleston, Denver, United States Of America; Paris, France)
| |
The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): A pooled analysis of outcomes in the CAPACITY (CAP) studies
C. Albera, W. Bradford, U. Costabel, T. King, P. Noble, S. Sahn, J. Szwarcberg, D. Valeyre, R. du Bois (Turin, Italy; Brisbane, San Francisco, Durham, Charleston, Denver, United States Of America; Essen, Germany; Paris, France)
| |
Extended analysis of phase III trial of pirfenidone: More pronounced effect in mild impairment of patients with idiopathic pulmonary fibrosis (IPF)
Y. Taguchi, M. Ebina, S. Hashimoto, T. Ogura, A. Azuma, H. Taniguchi, Y. Kondoh, M. Suga, H. Takahashi, K. Nakata, A. Sato, S. Kudoh, T. Nukiwa, Pirfenidone Clinical Study Group in Japan (Tenri City, Sendai, Yokohama, Tokyo, Aichi, Kumamoto, Japan)
| |
The effect of treatment with pirfenidone on death or lung transplantation in patients with idiopathic pulmonary fibrosis (IPF): Analysis of outcomes in the CAPACITY (CAP) trials
D. Valeyre, C. Albera, W. Bradford, U. Costabel, T. King, P. Noble, S. Sahn, J. Szwarcberg, R. du Bois (Paris, France; Turin, Italy; Brisbane, San Francisco, Durham, Charleston, Denver, United States Of America; Essen, Germany)
| |
Tolerance and efficacy of slow release octreotide in idiopathic pulmonary fibrosis. The FIBROSAND study
J. Chapron, Q. Dornic, M. P. Debray, M. Brauner, R. Lebtahi, P. Delaval, D. Israel-Biet, J. Lacronique, I. Monnet, M. Reynaud-Gaubert, A. Tazi, D. Valeyre, B. Wallaert, E. Bergot, F. Mentré, X. Duval, M. Dehoux, B. Crestani (Paris, Bobigny, Rennes, Créteil, Marseille, Lille, Caen, France)
| |
Oral administration of a new prostacyclin agonist with thromboxane synthase inhibitory activity improves bleomycin-induced lung fibrosis
A. Nakamura, K. Hamada, Y. Sakai, K. Matsumoto, H. Kimura (Osaka, Kanazawa, Japan)
| |
Treatment of exacerbations of fibrotic idiopathic interstitial pneumonias with cyclophosphamide and corticosteroids
E. Morawiec, V. Pansini, J. Salleron, M. Remy-Jardin, I. Tillie-Leblond, B. Wallaert (Lille, France)
| |